Spring Bank Pharmaceuticals, Inc.

Most Recent Annual Report

2017 Annual Report and Form 10K

Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals, Inc. has reached its limit for free report views.

About Spring Bank Pharmaceuticals, Inc.

11-50 Employees
Based in Hopkinton, Massachusetts

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Ticker:
SBPH
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol